Health and Fitness Health and Fitness
Tue, February 17, 2009
[ Tue, Feb 17th 2009 ] - Market Wire
AVANIR Announces Fiscal 2009 First Quarter Financial Results
[ Tue, Feb 17th 2009 ] - Market Wire
ReGen Biologics Announces Closing of Additional Financing
[ Tue, Feb 17th 2009 ] - Market Wire
Depomed Initiates Phase I Trial for DM-1992 Progr .. lowing Positive Results of Preclinical Studies Sp
[ Tue, Feb 17th 2009 ] - Market Wire
Flamel Technologies Announces Merck Serono?s Exer .. usa Technology for Development of an Extended-Rel
[ Tue, Feb 17th 2009 ] - Market Wire
St. Jude Medical Welcomes Introduction of Legislation to Help People Suffering From Pain
[ Tue, Feb 17th 2009 ] - Market Wire
BioSante Pharmaceuticals, Inc. Presents LibiGel® .. nical and Market Information at ISSWSH Conference
[ Tue, Feb 17th 2009 ] - Market Wire
Synta Earns $10 Million from GlaxoSmithKline for Achieving Elesclomol Milestone
[ Tue, Feb 17th 2009 ] - Market Wire
Affymax Announces $42 Million Private Placement
[ Tue, Feb 17th 2009 ] - Market Wire
China?s Shanghai Tumor Chooses the Mobetron for Advanced Cancer Care
[ Tue, Feb 17th 2009 ] - Market Wire
Experienced Cancer Researcher Joins Vitro?s Scientific Advisory Board
[ Tue, Feb 17th 2009 ] - Market Wire
Alnylam to Webcast Conference Call Discussing Fourth Quarter and 2008 Financial Results
[ Tue, Feb 17th 2009 ] - Market Wire
Sepracor Announces Tender Offer for 0% Convertible Senior Subordinated Notes Due 2024
[ Tue, Feb 17th 2009 ] - Market Wire
Acorda Therapeutics to Host Conference Call to Re .. Year 2008 Financial Results on February 24, 2009
[ Tue, Feb 17th 2009 ] - Market Wire
Inspire Announces Date for Conference Call and We .. urth Quarter and Full Year 2008 Financial Results
[ Tue, Feb 17th 2009 ] - Market Wire
California Hospital Implements ZOLL AutoPulse
[ Tue, Feb 17th 2009 ] - Market Wire
Natus Medical to Hold 2008 Fourth Quarter Financial Results Conference Call on February 26
[ Tue, Feb 17th 2009 ] - Market Wire
Phase 1 Trial Begins for Investigational New Drug for MDR Gram-negative Infections
[ Tue, Feb 17th 2009 ] - Market Wire
Zacks Bull & Bear of the Day Highlights: Baxter I .. nal, Marriott International, UDR, AIV and Vornado
[ Tue, Feb 17th 2009 ] - Market Wire
GTX Reports Fourth Quarter and Year End 2008 Results
Mon, February 16, 2009
[ Mon, Feb 16th 2009 ] - Market Wire
Constellation Software Inc.: Constellation Softwa .. Call to Discuss Fourth Quarter and Annual Results
[ Mon, Feb 16th 2009 ] - Market Wire
Wright Medical Group, Inc. to Participate in The Canaccord Adams Musculoskeletal Conference
[ Mon, Feb 16th 2009 ] - Market Wire
LifeVantage Corporation Announces the Addition of .. ing Network Marketing Distributors and Executives
[ Mon, Feb 16th 2009 ] - Market Wire
Applied Biosystems and Baylor College of Medicine .. ons to First Data Release of 1000 Genomes Project
Fri, February 13, 2009
[ Fri, Feb 13th 2009 ] - Market Wire
Signature Eyewear Reports Net Income for 2008
[ Fri, Feb 13th 2009 ] - Market Wire
Hypertension Diagnostics: Hypertension Diagnostics Announces FY 2009 Second Quarter Results
[ Fri, Feb 13th 2009 ] - Market Wire
Response Genetics Increasing Efficiency and Capac .. Certified Laboratory in Anticipation of Increased
[ Fri, Feb 13th 2009 ] - Market Wire
Genta Incorporated Announces Fourth Quarter and Y .. d 2008 Financial Results and Corporate Highlights
[ Fri, Feb 13th 2009 ] - Market Wire
Lpath, Inc.: Lpath to Present at the ROTH Capital Partners 21st Annual Growth Stock Conference
[ Fri, Feb 13th 2009 ] - Market Wire
Orthovita to Present at the Roth Capital Partners 21st Annual Growth Stock Conference
[ Fri, Feb 13th 2009 ] - Market Wire
Schaeffer's Street Stories: Cephalon Inc. Struggles with Staunch Technical Resistance

Schaeffer's Street Stories: Cephalon Inc. Struggles with Staunch Technical Resistance


Published on 2009-02-13 09:02:19, Last Modified on 2009-02-13 09:02:41 - Market Wire
  Print publication without navigation


CINCINNATI--([ BUSINESS WIRE ])--Pharmaceutical giant Cephalon Inc. (NASDAQ: CEPH) slipped into the earnings spotlight after the close last night to report that its fourth-quarter profit dropped, due to a large charge for ending a partnership on a drug to help alcoholics, and higher research and development costs. For the quarter, earnings rolled in at $1.46 per share, excluding items, beating the consensus estimate by 10 cents.

CEPH posted a net profit of $11.6 million, or 15 cents per share, compared with a net profit of $41.8 million, or 53 cents a share, a year ago. Revenue for the quarter rose 20% to $540.1 million, fueled by a 28% rise in sales of Provigil, for the sleep disorder narcolepsy, to $281.2 million. Analysts had predicted revenue of $525.9 million.

To continue reading this article, click here: [ http://www.schaeffersresearch.com/commentary/content/cephalon+inc+struggles+with+staunch+technical+resistance/observations.aspx?click=home&ID=91170&source=businesswire ]

Contributing Sources